Lykos Therapeutics Faces Leadership Changes Following FDA Disapproval of MDMA Therapy for PTSD
Lykos CEO Resignation Following FDA Rejection
Lykos Therapeutics is undergoing significant changes after the FDA recently rejected its MDMA-assisted therapy for post-traumatic stress disorder (PTSD). This setback prompted CEO Amy Emerson to resign, passing leadership to COO Michael Mullette temporarily.
Company Updates
Emerson, who has been integral to Lykos since its inception in 2014, will remain as a senior advisor until the end of 2024 and will continue participating on the company’s board. Lykos chairman Jeff George recognized her critical role, stating that her contributions have been pivotal in the mental health field and in pioneering the MDMA therapy pathway.
With Emerson’s departure, Lykos appointed David Hough as Chief Medical Officer, emphasizing continued efforts to enhance its MDMA therapy alongside required FDA guidance for resubmission processes. Lykos’s recent struggles underscore the challenges faced by biotech companies amid stringent regulatory scrutiny.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.